| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3991985 | Journal of Thoracic Oncology | 2010 | 7 Pages |
Abstract
FFS or PFS at 12 weeks is a stronger predictor of subsequent patient survival compared with tumor response and should be routinely used as endpoints in phase II trials for advanced non-small cell lung cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Sumithra J. PhD, Yingwei MD, MS, Shauna L. MS, Katie L. BS, Nicholas F. MD, Kendrith M. MD, Steven A. MD, Randolph S. MD, Steven E. MD, Alex A. MD, PhD,